Scientists engineer CRISPR system that selectively destroys p53-mutant cancer cells
Researchers led by Jennifer Doudna engineered a CRISPR system that detects mutant p53 cancer cells and triggers their self-destruction, offering a new strategy against one of oncology's most stubborn targets.
By Ryan Merket · Published
Why it matters
The result points to a different cancer-editing playbook: using CRISPR as a selective kill switch rather than a repair tool. The hard part remains delivery.
Researchers affiliated with the Innovative Genomics Institute have developed a CRISPR-based system that selectively kills cancer cells carrying mutations in the p53 tumor suppressor gene, one of the most common genetic drivers of human cancer.
The work, published in the journal Nature, describes an experimental approach that uses CRISPR not to repair damaged DNA, but to identify cancer cells and trigger their destruction from within.
According to a June 8 announcement from the Innovative Genomics Institute (IGI), the technique targets mutant forms of p53, a gene altered in roughly half of all cancers. Despite decades of research and billions of dollars invested across the oncology industry, mutant p53 has largely resisted conventional drug development efforts.
"Not only can this approach target the 'undruggable' cancers that we know, we can also easily and quickly adapt this to new mutations," said Jennifer Doudna, founder of IGI, Nobel Prize-winning co-inventor of CRISPR gene editing technology, and a co-author on the study.
The research was conducted by scientists from IGI, the University of California, Berkeley, the University of California, San Francisco, the Gladstone Institutes, the University of Utah, and Utah State University.
A different way to think about gene editing
Most CRISPR programs are designed around correcting or repairing disease-causing mutations. The team behind the new study took a different approach.
Rather than attempting to fix mutant p53, first author Jingkun Zeng and colleagues engineered a version of the CRISPR-associated enzyme Cas12a2 to act as a molecular sensor. The system detects RNA transcripts produced specifically by cells carrying the mutant gene.
Once activated, Cas12a2 initiates what researchers describe as "chromatin shredding," cutting genetic material throughout the cell. The resulting damage is severe enough to trigger cell death.
In effect, the system functions as a highly targeted self-destruct mechanism. Cells expressing the mutant cancer signal are destroyed, while cells lacking that signal are intended to remain untouched.
The strategy transforms CRISPR from a gene-editing tool into a mutation-guided cancer cell killer.
Why p53 matters
The p53 protein is often called the "guardian of the genome" because it helps prevent damaged cells from becoming cancerous. When the gene is mutated, cells can evade normal growth controls and accumulate additional genetic abnormalities.
Scientists have been studying p53-driven cancers since the late 1980s. Yet despite its central role in oncology, directly targeting mutant p53 has proven extraordinarily difficult.
Many cancer drugs work by blocking proteins with well-defined molecular structures. Mutant p53 proteins often lack obvious binding sites for traditional medicines, leading researchers to categorize them as "undruggable" targets.
That challenge has made p53 one of the most sought-after objectives in cancer drug development.
The new CRISPR approach sidesteps the problem entirely. Instead of trying to restore or inhibit mutant p53, it uses the mutation itself as a signal that marks the cell for elimination.
Still far from the clinic
While the findings are scientifically significant, they do not represent a cancer treatment ready for patients.
The work remains at the laboratory stage, and major hurdles remain before any CRISPR-based cancer-killing system could become a viable therapy.
The biggest challenge is delivery. Researchers must demonstrate they can safely transport the CRISPR machinery into enough tumor cells inside the human body while avoiding healthy tissue. Delivery has been one of the most persistent obstacles facing CRISPR oncology programs across the industry.
Additional studies will also be required to establish safety, effectiveness, durability, and the potential for unintended effects before human testing could begin.
Still, the research highlights a growing trend in gene editing: using CRISPR not only to rewrite genetic code, but also as a programmable biological sensor capable of identifying and eliminating diseased cells.
For cancers driven by mutations that conventional drug discovery has struggled to reach, that shift could open an entirely new therapeutic playbook.